This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Jiangsu Theravac Bio-Pharmaceutical Co., Ltd.. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: Innovator in Hepatitis B Vaccine Research: Meiju Wang
Introduction: Meiju Wang, an accomplished inventor based in Nanjing, China, has made significant contributions to the field of biotechnology, particularly in the development of vaccines for infectious diseases. With a strong focus on Hepatitis B, her innovative work aims to enhance treatment options and improve health outcomes for patients worldwide.
Latest Patents: Meiju Wang holds a patent for a novel composition used in the creation of a Hepatitis B vaccine. The patent discloses a composition comprising HBsAg, variants or fragments thereof, HBcAg1-X, and a specific phosphorothioate oligonucleotide, CpG-ODN. This innovative composition not only targets HBV infection but also provides therapy methods for HBV-induced diseases, showcasing her expertise and dedication to addressing global health challenges.
Career Highlights: Currently, Meiju Wang is associated with Jiangsu Theravac Bio-pharmaceutical Co., Ltd., where she plays a pivotal role in advancing biopharmaceutical research and vaccine development. Her commitment to innovation in vaccine technology is evidenced by her successful patent application, positioning her as a key figure in the biotechnology sector.
Collaborations: Throughout her career, Meiju has collaborated with esteemed colleagues such as Sean Xiaohan Du and Jun Ge, contributing to a dynamic and innovative team environment. These collaborations have been instrumental in enhancing research efforts and fostering breakthroughs in vaccine development.
Conclusion: Meiju Wang stands out as a remarkable inventor dedicated to improving public health through her innovative work in vaccine research. Her contributions, particularly in the area of Hepatitis B, reflect her passion for innovation and her commitment to advancing medical science. As she continues her work at Jiangsu Theravac Bio-pharmaceutical Co., Ltd., her future endeavors promise to bring further advancements to the field of biotechnology and infectious disease treatment.